News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,910 Results
Type
Article (39153)
Company Profile (283)
Press Release (648474)
Section
Business (203904)
Career Advice (1996)
Deals (35375)
Drug Delivery (89)
Drug Development (80854)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344652)
Policy (32452)
Tag
Academia (2530)
Alliances (49185)
Alzheimer's disease (1257)
Approvals (16050)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64699)
Collaboration (483)
Compensation (260)
COVID-19 (2541)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110006)
Executive appointments (394)
FDA (16769)
Funding (426)
Gene therapy (195)
GLP-1 (598)
Government (4333)
Healthcare (18693)
Infectious disease (2633)
Inflammatory bowel disease (112)
Interviews (309)
IPO (16340)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19195)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (184)
Patents (117)
People (56455)
Phase I (20119)
Phase II (28495)
Phase III (21243)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21667)
Research institute (2310)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Today (2)
Last 7 days (580)
Last 30 days (2330)
Last 365 days (35180)
2024 (35005)
2023 (40079)
2022 (51173)
2021 (55711)
2020 (54087)
2019 (46541)
2018 (35023)
2017 (32112)
2016 (31481)
2015 (37552)
2014 (31318)
2013 (26345)
2012 (28570)
2011 (29263)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37269)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79828)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,910 Results for "fibrogen inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Bay
FibroGen Announces Clinical Trial Supply Agreement with Regeneron Pharmaceuticals to Evaluate FibroGen’s Immuno-Oncology Assets, FG-3165 (anti-Galectin 9) and FG-3175 (anti-CCR8), in Combination with LIBTAYO® in Upcoming Clinical Trials
FibroGen, Inc. (NASDAQ: FGEN) today announced a clinical trial supply agreement with Regeneron Pharmaceuticals to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in combination with Regeneron’s anti-PD-1 therapy, LIBTAYO® (cemiplimab), in patients with solid tumors.
June 3, 2024
·
5 min read
Layoffs
FibroGen to Lay Off 127 Workers in San Francisco
FibroGen expects its headcount reduction, which is tied to eliminating 75% of its U.S. workforce, to be mostly complete by the end of the first quarter of 2025.
August 12, 2024
·
1 min read
·
Angela Gabriel
Press Releases
FibroGen Appoints David DeLucia as Chief Financial Officer
December 16, 2024
·
4 min read
Biotech Bay
FibroGen to Participate in Upcoming May 2024 Investor Conferences
FibroGen, Inc. announced that the company’s management will participate in the following investor conferences.
May 7, 2024
·
1 min read
Business
FibroGen Reports First Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the first quarter 2024 and provided an update on the company’s recent developments.
May 6, 2024
·
11 min read
Business
FibroGen to Report First Quarter 2024 Financial Results
FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2024 financial results on Monday, May 6 after the market close.
April 29, 2024
·
1 min read
Press Releases
FibroGen Reports Third Quarter 2024 Financial Results
November 13, 2024
·
10 min read
Press Releases
FibroGen to Report Third Quarter 2024 Financial Results
November 4, 2024
·
1 min read
Biotech Bay
FibroGen to Present at Goldman Sachs 45th Annual Global Healthcare Conference
FibroGen, Inc. announced that Thane Wettig, Chief Executive Officer, will participate in a Fireside Chat at Goldman Sachs 45th Annual Global Healthcare Conference to be held in Miami, Florida on Monday, June 10, 2024, from 10:00-10:35 AM Eastern Time.
June 3, 2024
·
1 min read
Biotech Bay
FibroGen to Host Part II of Virtual KOL Investor Event Series to Review FG-3246 Development Program in Metastatic Castration-Resistant Prostate Cancer on June 26, 2024
FibroGen, Inc. (NASDAQ: FGEN) today announced it will host the second part of its virtual KOL investor event series on Wednesday, June 26, 2024 at 10:00 AM ET.
June 18, 2024
·
5 min read
1 of 68,791
Next
